The Medicare Payment Advisory Commission (MedPAC) released its annual report on March 12, 2026, projecting that the federal government will spend approximately 14% more per beneficiary enrolled in a Medicare Advantage (MA) plan than it would for those same beneficiaries under traditional, fee-for-service Medicare. The differential translates to an estimated $76 billion in excess payments to private health insurance companies administering MA plans during the current fiscal year, representing one of the largest documented overpayment figures the commission has reported to date.

MedPAC, an independent nonpartisan body established by the Balanced Budget Act of 1997, advises Congress on payment policies across Medicare programs. The commission has documented excess MA payments in prior annual reports, but the scale of the 2026 projection has drawn renewed scrutiny from federal legislators and health policy analysts who monitor the program’s financial trajectory.

The Overpayment Mechanism

The disparity between MA and traditional Medicare spending arises through several interrelated payment mechanisms. MA plans receive monthly capitated payments from the Centers for Medicare and Medicaid Services (CMS) for each enrolled beneficiary, with payment amounts adjusted upward based on beneficiaries’ documented health conditions. This risk-adjustment system is intended to compensate insurers for enrolling sicker patients who require more care.

MedPAC and independent researchers have documented, across multiple reporting cycles, that MA insurers systematically record diagnoses at higher rates than traditional Medicare providers document for comparable patient populations. This practice, commonly referred to as “upcoding,” inflates risk scores and, consequently, the capitated payments insurers receive from the federal government, without necessarily reflecting a corresponding increase in the clinical complexity of the enrolled population or the actual services provided.

The commission’s methodology for calculating excess payments compares per-capita MA spending against what CMS would have paid for the same beneficiaries under traditional Medicare, adjusting for observable demographic and clinical characteristics. Critics of the MedPAC methodology, including several industry-aligned advocacy organizations, dispute both the analytical assumptions underlying these comparisons and the commission’s characterization of the resulting differential as an “overpayment.”

Industry Resistance and Legislative Pressure

The release of the 2026 report has coincided with a marked escalation in organized opposition from health insurance industry lobbying groups. Organizations including the Better Medicare Alliance and the Healthcare Leadership Council have publicly challenged the validity of MedPAC’s findings and promoted alternative analyses that frame MA payment levels as appropriate or insufficient relative to the value the program delivers to beneficiaries.

Both organizations have endorsed an editorial published in the Wall Street Journal that, among other arguments, called for MedPAC itself to be defunded. The editorial represents a notable sharpening of industry rhetoric, moving from methodological critique toward an argument that the commission’s independent advisory function should be eliminated entirely.

Industry groups have also advanced legislative efforts that would impose constraints on how MedPAC’s staff conduct research and develop payment recommendations. Supporters of such legislation argue that the commission’s analytical methods require greater external oversight and standardization. MedPAC and its congressional supporters characterize these efforts as attempts to subordinate independent Medicare payment analysis to the financial interests of private insurers.

The lobbying campaign extends to the executive branch. Industry groups have applied pressure on the Trump administration to increase MA payment benchmarks in the upcoming rate-setting cycle, a position at odds with MedPAC’s recommendations to reduce or eliminate the documented overpayment differential. CMS annually updates MA payment rates through a Notice of Final Payment and Policy, and the administration’s rate decisions carry immediate and substantial financial consequences for participating insurers.

Program Scale and Enrollment Context

Medicare Advantage has expanded substantially over the prior decade. As of 2026, MA enrollment accounts for more than half of all Medicare-eligible beneficiaries, with approximately 34 million individuals enrolled in private plans. The program’s growth has been accompanied by proportional increases in federal expenditures, and the absolute dollar magnitude of any per-beneficiary payment differential scales accordingly.

The $76 billion excess payment figure cited by MedPAC represents the aggregate annual cost of the 14% differential across the full enrolled MA population. To contextualize that figure, total Medicare spending across all program components is projected to approach $1.1 trillion in fiscal year 2026. The MA overpayment, by MedPAC’s calculation, therefore represents approximately 7% of total program expenditure, a considerable share given Medicare’s structural role in federal budget projections.

Congressional Budget Office projections identify Medicare as among the primary drivers of long-term federal deficit growth. Against that backdrop, MedPAC’s annual documentation of excess MA payments carries policy weight beyond the immediate fiscal year, informing multi-year budget negotiations and, periodically, legislative reforms to the program’s payment structure.

Clinical and Policy Implications for Beneficiaries

The policy debate over MA payment levels carries direct implications for beneficiaries enrolled in the program, though the relationship between payment adequacy and care quality is contested in the literature. Insurers participating in MA argue that enhanced payment rates fund supplemental benefits, including dental, vision, hearing, and over-the-counter allowances, that traditional Medicare does not cover. These supplemental offerings have been a primary driver of MA enrollment growth and represent a genuine expansion of coverage for many beneficiaries.

MedPAC’s position does not dispute that MA plans offer supplemental benefits. Rather, the commission argues that the excess payment differential funds those benefits and insurer profit margins at a level that exceeds what would be required to sustain a competitively priced program offering comparable coverage. The commission has recommended that Congress recalibrate payment benchmarks to align MA payments more closely with projected traditional Medicare costs for equivalent populations.

Opponents of payment reductions caution that lower benchmarks could prompt insurers to reduce supplemental benefit offerings, increase cost-sharing, or exit markets in lower-density or rural service areas where per-capita costs are higher and enrollment volumes less favorable to plan economics. Several MA insurers announced benefit reductions and market exits in rural counties during the 2025 enrollment period, a development industry representatives attributed in part to prior CMS rate adjustments.

CMS data on plan availability and benefit design indicate that rural beneficiaries have experienced reduced MA plan options in certain geographies over the prior two enrollment cycles, though the causal relationship to federal payment policy versus other market factors remains a subject of ongoing analytical work by MedPAC and independent researchers.

MedPAC’s Independence Under Scrutiny

The commission’s statutory independence from executive branch direction and its mandate to provide objective analysis to Congress have historically insulated MedPAC from direct political intervention in its research agenda. The current industry-backed legislative effort to regulate the commission’s research methodology represents a structural challenge to that independence, distinct from the substantive disagreements over payment calculations that have characterized prior cycles of debate.

Congressional supporters of MedPAC’s independent function have pushed back against the proposed legislative constraints, arguing that imposing external methodological requirements on commission staff would effectively allow financially interested parties to shape the analytical framework through which federal Medicare payment policy is evaluated. That argument has not yet produced definitive legislative action, but the debate is expected to continue as Congress moves toward annual budget and appropriations deliberations in the coming months.

The tension between MedPAC’s advisory mandate and the financial interests of the MA industry is not novel. The commission has documented excess payments across multiple prior administrations and congressional configurations, and the insurance sector’s lobbying apparatus has consistently sought to moderate the policy response to those findings. What distinguishes the current period is the directness of the effort to challenge the commission’s institutional standing rather than solely contesting its conclusions.

Rate-Setting Outlook

CMS is expected to release the final MA payment rates for contract year 2027 in the coming weeks. The rate notice will reflect the administration’s decisions regarding payment benchmarks, risk-adjustment methodology, and the treatment of the quality bonus payment system that currently allows MA plans to receive above-benchmark payments for meeting specified performance thresholds.

MedPAC’s annual report will serve as a reference document for legislators and advocates on both sides of the payment debate as the rate-setting process concludes. Whether the administration’s final rate decisions align with the commission’s recommendations for payment recalibration, or reflect the industry’s argument for increased funding, will serve as an early indicator of how the current federal government weighs independent advisory findings against organized industry opposition in the MA payment context.

The commission’s report is available in full on the MedPAC website. Congressional testimony related to the report’s findings is scheduled for the coming weeks before relevant House and Senate committees with jurisdiction over Medicare payment policy.